| Brand Name (Generic Name) | Kynmobi™ [kin-MOE-bee] (apomorphine hydrochloride) [a-poe-MOR-feen] |
| How Supplied | 10 mg, 15 mg, 20 mg, 25 mg, and 30 mg sublingual (SL) film |
| Therapeutic Class | Non-ergoline dopamine agonist |
| Approved Indication | Acute intermittent treatment of OFF episodes in those with Parkinson’s disease |
| Usual Dosing | 10 mg to 30 mg per dose sublingually (SL) as needed; doses should be separated by at least 2 hours. Maximum single dose of 30 mg and a maximum of 5 doses per day. |
| Select Drug Interactions | Use with 5-HT3 antagonists (e.g., ondansetron, granisetron) is contraindicated due to the risk of profound hypotension and loss of consciousness. Use with antihypertensives and vasodilators may increase the risk for hypotension, myocardial infarction, falls, and injuries. Dopamine antagonists (e.g., haloperidol, metoclopramide) may reduce the effectiveness of Kynmobi. |
| Most Common Side Effects | Nausea, oral/pharyngeal soft tissue pain and paraesthesia, oral/pharyngeal soft tissue swelling, dizziness, and somnolence |
| Miscellaneous | Dose initiation should be supervised by a healthcare provider. Concomitant treatment with an antiemetic (e.g., trimethobenzamide) is recommended beginning 3 days prior to initial dose of Kynmobi™. Avoid abrupt discontinuation. |
| Website | https://www.kynmobi.com |
New Drug – Kynmobi™ Sublingual Film
By Dave Pregizer
